PIRS - Pieris Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.2900
-0.1700 (-4.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.4600
Open3.4400
Bid3.2800 x 2200
Ask3.2900 x 900
Day's Range3.2800 - 3.4600
52 Week Range2.3900 - 6.0400
Volume428,107
Avg. Volume725,915
Market Cap181M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.7150
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
  • Gene Therapy the Next Best Thing: Here's Why (Revised)
    Zacks

    Gene Therapy the Next Best Thing: Here's Why (Revised)

    Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

  • Thomson Reuters StreetEvents

    Edited Transcript of PIRS earnings conference call or presentation 11-Nov-19 1:00pm GMT

    Q3 2019 Pieris Pharmaceuticals Inc Earnings Call

  • Does Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Pay Matter?
    Simply Wall St.

    Does Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Pay Matter?

    Steve Yoder became the CEO of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in 2014. First, this article will compare CEO...

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • Benzinga

    The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

    Biotech stocks went about a consolidation move last week, although a few swung wildly in either direction in reaction to some catalytic events. Aslan  (NASDAQ: ASLN ) tumbled  after its late-stage biliary ...

  • ACCESSWIRE

    Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh

    BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced a research collaboration between the Company and the labs of University of Pittsburgh Professors Sally Wenzel, MD, and Anuradha Ray, PhD, focused on comprehensive immune phenotyping of severe asthmatic patients. Key objectives of the multi-year collaboration include patient stratification strategies for more streamlined development of therapeutic interventions as well as identifying and validating novel asthma targets. Professors Wenzel and Ray's research efforts have focused on comprehensive long-term assessments of asthma patients, including responsiveness to a range of therapies.

  • ACCESSWIRE

    Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

    The Company will conduct one-on-one meetings with institutional investors at this conference. A webcast of the Company's presentation will be available at this link. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way.

  • Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates

    Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE

    Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM EST BOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology ...

  • ACCESSWIRE

    Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

    BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the presentation of data from the phase 1 dose-escalation monotherapy study of PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Beyond demonstrating clinical benefit, PRS-343 showed a potent increase in CD8+ T cell numbers and proliferative index in the tumor microenvironment of responders, indicative of 4-1BB agonism on T cells. "The data presented today demonstrate PRS-343's potential to make a meaningful difference for patients with tumors that are difficult to treat with currently-available therapies," said Geoffrey Y. Ku, medical oncologist at Memorial Sloan Kettering and the principal investigator for the PRS-343 monotherapy trial.

  • ACCESSWIRE

    Pieris Pharmaceuticals to Host R&D Event

    BOSTON, MA / ACCESSWIRE / November 7, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology ...

  • 3 Names Making the Case That Investing in Small Biotech Is Never Dull
    TheStreet.com

    3 Names Making the Case That Investing in Small Biotech Is Never Dull

    Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.

  • ACCESSWIRE

    Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology ...

  • ACCESSWIRE

    Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

    BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it has entered into a securities purchase agreement with existing and new institutional investors to raise $32 million. The private placement was led by BVF Partners L.P., with significant additional participation from EcoR1 Capital, Aquilo Capital Management, Surveyor Capital (a Citadel company), and Samsara BioCapital. The private placement will consist of 9,014,960 units, at a price of $3.55 per unit.

  • ACCESSWIRE

    Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019

    BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...

  • Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
    Simply Wall St.

    Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • ACCESSWIRE

    Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress

    BOSTON, MA / ACCESSWIRE / September 26, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation on October 1, 2019, of interim data from its placebo-controlled multiple ascending dose phase 1b study for AZD1402/PRS-060, an inhaled IL4-Rα antagonist being developed in collaboration with AstraZeneca intended for the treatment of asthma, at the 2019 European Respiratory Society International Congress. The poster, available on the Congress Website, is titled "Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," and reported that AZD1402/PRS-060 was safe and well tolerated at all doses, significantly reduced fractional exhaled nitric oxide (FeNO) - a validated biomarker or eosinophilic airway inflammation, and showed dose-dependent systemic target engagement in patients with mild asthma and elevated levels of FeNO (≥ 35ppb).

  • ACCESSWIRE

    Pieris Pharmaceuticals Announces Changes to Senior Management Team

    BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the appointment of Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer and the departure of Allan Reine, M.D., Senior Vice President and Chief Financial Officer. Dr. Kaufmann will be responsible for the Company’s drug discovery, protein engineering and biomanufacturing activities, while overseeing alliance management and serving as site head for its German R&D facility.

  • Thomson Reuters StreetEvents

    Edited Transcript of PIRS earnings conference call or presentation 1-Aug-19 12:00pm GMT

    Q2 2019 Pieris Pharmaceuticals Inc Earnings Call

  • Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), then you might want to consider its beta (a...

  • ACCESSWIRE

    Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update

    BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today reported its cash position for the second quarter of 2019 ended June 30, 2019, and provided an update on the Company's recent and future developments. “In the first half of 2019, we made significant progress on our clinical milestones, and we expect that momentum to build into the end of the year,” said Stephen S. Yoder, President and Chief Executive Officer of Pieris. “Last quarter, we presented two clinical data sets, including data from the phase 1 single ascending dose study of PRS-060, an inhaled IL-4 receptor alpha antagonist for moderate-to-severe asthma that was found to be safe and well-tolerated in the study and demonstrated favorable pharmacokinetics and robust target engagement.

  • ACCESSWIRE

    Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors

    BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors. Dr. Said is the Founder and Chief Executive Officer of Outcomes4Me Inc., a health technology company focused on providing patients diagnosed with cancer and other chronic life altering diseases with personalized treatment options as well as outcomes information.

  • Schaeffer's Investment Research

    PIRS Stock Surges on Promising Drug Data Ahead of Earnings

    The European Respiratory Society accepted Pieris' asthma presentation

  • ACCESSWIRE

    Pieris Pharmaceuticals To Host Second Quarter 2019 Investor Call And Corporate Update On August 1, 2019

    BOSTON, MA / ACCESSWIRE / July 25, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology ...